A phase II study of panitumumab for refractory pateients to standard treatments with KRAS wild type advenced colorectal cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000004654
- Lead Sponsor
- Department of Gastroenterological Surgery
- Brief Summary
Results of this study demonstrate that tri-weekly panitumumab treatment is a promising regimen offering benefits in terms of convenience and safety in patients with advanced colorectal cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
1) Patients who have allergy for drugs are excluded. 2) Patients who have other malignancies are excluded. 3) Patients who have infections in active are excluded. 4) Patients who have past histories of bowel perforation and / or bowel obstruction in one year before registration are excluded. 5) Patients who have severe diseases are excluded. 6) Patients who have pleural effusion and / or ascites to need treatment are excluded. 7) Patients who have watery diarrhea are excluded. 8) Patients who have symptomatic brain metastasis are excluded. 9) Patients who have pregnancy are excluded. 10) Patients who receive steroid continuously are excluded. 11) Patients who have past histories of cerebral infarction, cardiac infarction and / or pulmonary infarction are excluded. 12) Patients whom physicians decide to exclude are ineligible. 13) The patient that a study responsibility physician judged to be inappropriate.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method frequency of Adverse events tumor regression rate Progression-free survival Overall survival Treatment completion rate Time to treatment failure